GALT

Galectin Therapeutics Inc. Press Releases

$10.92
*  
0.07
 negative 
0.65%
Get GALT Alerts
*Delayed - data as of Apr. 15, 2014 
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By

First Cohort Results in Galectin Therapeutics' Phase 1 Trial Reveal Biomarker Evidence of Therapeutic Effect on Fibrosis and Inflammation in NASH With Advanced Fibrosis
3/31/2014 4:30:00 PM - GlobeNewswire

Galectin Therapeutics to Announce Results From First Cohort of Phase 1 Clinical Trial in Fatty Liver Disease
3/25/2014 8:00:00 AM - GlobeNewswire

Galectin Therapeutics Reports 2013 Financial Results
3/21/2014 4:45:00 PM - GlobeNewswire

Galectin Therapeutics Secures U.S. Patent for its Proprietary Galectin Inhibitor GR-MD-02 in Fatty Liver Disease
2/26/2014 8:00:00 AM - GlobeNewswire

Galectin Therapeutics Presents at JMP Securities' Nonalcoholic Steatohepatitis (NASH) Workshop
2/24/2014 10:00:00 AM - GlobeNewswire

Galectin Therapeutics CEO Serves on Cancer Immunotherapy Panel at BIO CEO & Investor Conference
2/13/2014 8:00:00 AM - GlobeNewswire

Galectin Therapeutics to Present at 16th Annual BIO CEO & Investor Conference
2/5/2014 8:15:00 AM - GlobeNewswire

Galectin Therapeutics and Providence Portland Medical Center Receive OK From FDA to Proceed With Phase 1B Clinical Trial in Metastatic Melanoma
2/3/2014 11:30:00 AM - GlobeNewswire

Galectin Therapeutics Inc. and SBH Sciences, Inc. Announce the Formation of Galectin Sciences, LLC, a Collaborative Venture to Research and Develop Galectin Inhibitors for Oral Administration
1/27/2014 8:15:00 AM - GlobeNewswire

Galectin Therapeutics Executive Chairman James Czirr to Present at RedChip Emerging Growth Showcase
1/23/2014 10:30:00 AM - GlobeNewswire

Preclinical Study Demonstrates Effect of Galectin Inhibitor on Serum Biomarker in Fatty Liver Disease With Fibrosis
1/21/2014 8:00:00 AM - GlobeNewswire